Head and neck cancer treatment has evolved significantly as researchers have developed new ways to attack cancer cells and help the immune system recognize tumors. Combination therapies bring together two or more treatments, such as chemotherapy, immunotherapy, targeted therapy, or radiation, to improve cancer control and potentially extend survival.
Head and neck cancers can develop in the mouth, throat, voice box, nasal cavity, and other structures. Treatment depends on where the cancer begins, its stage, and whether it has spread.
THE BASICS: Combination therapies are an important part of head and neck cancer care. Established approaches include chemotherapy with radiation therapy, cetuximab with radiation or chemotherapy, and immunotherapy with chemotherapy. New combinations involving cancer vaccines, targeted drugs, and other treatments are being studied in clinical trials.
What are combination therapies for head and neck cancer?
Combination therapy uses two or more treatments to attack cancer through different mechanisms. One treatment may directly damage cancer cells while another blocks tumor growth signals or helps the immune system recognize cancer.
For example, chemotherapy can make cancer cells more sensitive to radiation, while immunotherapy may help immune cells recognize and destroy tumors.
These approaches may be used as the primary treatment, before surgery to shrink a tumor, after surgery to reduce recurrence risk, or for recurrent or metastatic disease.
Not every combination is appropriate for every patient. Your oncology team will recommend a treatment plan based on your diagnosis and overall health.
How do head and neck cancer types affect treatment?
Head and neck cancer includes several cancer types that develop in different anatomical locations. These include:
Oral cancer: Cancer of the lips, tongue, gums, and other structures in the oral cavity.
Oropharyngeal cancer: Cancer involving the tonsils, base of the tongue, and other parts of the oropharynx.
Laryngeal cancers: Cancers that begin in the larynx, or voice box.
Nasopharyngeal cancer: Cancer that develops in the upper throat behind the nose.
Salivary gland cancer: Cancer arising in the salivary glands, which produce saliva.
Although these cancers share some treatment approaches, their biology and recommended therapies can differ.
For example, oropharyngeal cancer treatment may be influenced by human papillomavirus (HPV) status, while nasopharyngeal cancer has distinct treatment strategies and immunotherapy approvals.
The following combinations apply to specific head and neck cancer populations rather than every cancer in this group.
Targeted therapy for head and neck cancer treatment
Targeted therapies interfere with specific proteins or pathways that help cancer cells grow and survive.
Cetuximab plus radiation therapy
Cetuximab (Erbitux) is a monoclonal antibody that blocks the epidermal growth factor receptor (EGFR), a protein involved in cancer cell growth.
Cetuximab combined with radiation therapy is an established option for selected patients with locally advanced head and neck squamous cell carcinoma who cannot receive cisplatin.
Cetuximab is generally administered through an intravenous infusion during the radiation treatment course.
However, cetuximab with radiation should not be considered equivalent to cisplatin-based chemoradiation. Studies in HPV-positive oropharyngeal cancer have demonstrated worse cancer outcomes with cetuximab compared with cisplatin, despite expectations that cetuximab might be less toxic.
Cetuximab plus chemotherapy
Cetuximab may also be combined with platinum-based chemotherapy and fluorouracil, a combination known as the EXTREME regimen.
This regimen improved median overall survival from 7.4 months with chemotherapy alone to 10.1 months when cetuximab was added in a landmark clinical trial involving recurrent or metastatic head and neck squamous cell carcinoma.
Although the regimen helped establish combination treatment for advanced disease, immunotherapy-based approaches have since become important first-line options for many patients.
The EXTREME regimen can cause significant side effects, so treatment decisions depend on overall health, organ function, and other available therapies.
Immunotherapy and chemotherapy combinations
Immunotherapy helps the body's immune system recognize and attack cancer cells. Immune checkpoint inhibitors work by blocking signals that prevent immune cells from responding effectively to cancer.
Combining immunotherapy with chemotherapy may improve outcomes by attacking cancer through complementary mechanisms.
Pembrolizumab plus chemotherapy
Pembrolizumab (Keytruda) is a PD-1 checkpoint inhibitor used in several head and neck cancer treatment settings.
For recurrent or metastatic head and neck squamous cell carcinoma, pembrolizumab combined with platinum chemotherapy and fluorouracil is an established first-line treatment option.
The combination can be used regardless of PD-L1 expression, although biomarker results and individual circumstances may influence treatment selection.
Pembrolizumab also has an approved perioperative role for certain patients with resectable, locally advanced, PD-L1-positive head and neck squamous cell carcinoma. In this setting, it is administered before surgery and continued afterward with radiation, with or without cisplatin, followed by additional pembrolizumab.
These are distinct treatment approaches, and patients should discuss which setting applies to their diagnosis.
Toripalimab plus chemotherapy
Toripalimab (Loqtorzi) is another PD-1 inhibitor. It is approved in combination with gemcitabine and cisplatin for first-line treatment of adults with metastatic or recurrent, locally advanced nasopharyngeal carcinoma.
In the phase III JUPITER-02 trial, adding toripalimab to chemotherapy improved outcomes compared with chemotherapy alone.
Long-term results reported median overall survival of approximately 64.8 months with toripalimab plus chemotherapy versus 33.7 months with chemotherapy alone.
This approval applies specifically to nasopharyngeal carcinoma and should not be generalized to all head and neck cancers.
Nivolumab and other immunotherapy treatment options
Nivolumab (Opdivo) is a PD-1 inhibitor approved for recurrent or metastatic head and neck squamous cell carcinoma that progresses during or after platinum-based chemotherapy.
It works by blocking an immune checkpoint that can prevent T cells from attacking cancer cells.
Researchers are also studying nivolumab in combination with other cancer treatments, including chemotherapy, targeted therapies, and radiation.
Some studies have investigated whether adding nivolumab to treatment before surgery can improve tumor response. Other research has explored immunotherapy after definitive treatment to reduce recurrence risk.
These approaches should be distinguished from established FDA-approved treatment indications.
Chemotherapy and radiation therapy for head and neck cancer
Combining chemotherapy with radiation, called chemoradiation, is a standard approach for many patients with locally advanced head and neck squamous cell carcinoma.
Cisplatin is one of the most commonly used chemotherapy drugs in this setting. It can make cancer cells more sensitive to radiation, improving the ability of radiation to destroy tumors.
Chemoradiation may be recommended when preserving an organ, such as the larynx, is a treatment priority or when cancer characteristics make combined treatment appropriate.
However, side effects can include mouth sores, difficulty swallowing, fatigue, nausea, hearing changes, kidney problems, and long-term swallowing difficulties.
Your medical oncologist and radiation oncologists will evaluate whether the potential benefits outweigh the risks.
Proton therapy and other radiation treatment types
Radiation treatment has become increasingly precise, allowing doctors to target tumors while limiting exposure to nearby healthy structures.
Proton therapy uses proton beams rather than traditional X-rays. Its physical properties may reduce radiation exposure to certain healthy tissues, depending on tumor location and treatment planning.
For selected head and neck cancers, proton therapy may help reduce radiation exposure to structures involved in swallowing, saliva production, or other functions.
Other radiation options include intensity-modulated radiation therapy (IMRT) and, in selected situations, brachytherapy, which places radioactive material inside or near a tumor.
Proton therapy is not automatically more effective than conventional radiation for every patient. The best approach depends on the cancer's location, stage, available evidence, and treatment goals.
Surgery combined with other cancer treatments
Surgery may be used alone for selected early-stage head and neck cancers or combined with radiation, chemotherapy, or immunotherapy.
When a tumor can be removed, surgery may be the initial treatment. Radiation or chemoradiation may follow if pathology identifies features associated with a higher risk of recurrence.
Researchers are also investigating treatments given before surgery, called neoadjuvant therapy, to shrink tumors and stimulate immune responses.
Combining surgery with other therapies requires careful planning because treatment can affect speech, swallowing, appearance, and quality of life.
Emerging targeted therapies in clinical trials
Several promising approaches are being studied to overcome resistance to conventional treatments.
Bispecific antibodies plus immunotherapy
Bispecific antibodies are laboratory-made proteins designed to bind to two different targets.
Petosemtamab, which targets EGFR and LGR5, and BCA101, which targets EGFR and TGF-beta, are examples of investigational agents being studied with pembrolizumab or other treatments.
Researchers hope these combinations will improve immune activity and tumor control, particularly in advanced cancer.
Cancer vaccines plus immunotherapy
Therapeutic cancer vaccines are designed to stimulate immune responses against proteins associated with tumors.
PDS0101, also called Versamune HPV, has been investigated with pembrolizumab for recurrent or metastatic HPV16-positive head and neck cancer.
Early studies have reported encouraging survival and antitumor activity in selected patients, including an overall survival estimate of 39.3 months in a reported study population.
However, these findings require confirmation in larger randomized studies before the combination can become an established treatment.
Radioenhancers and novel radiation combinations
Radioenhancers are experimental agents designed to increase the effect of radiation on cancer cells.
NBTXR3 is a nanoparticle-based radioenhancer being investigated in head and neck cancer. It is injected directly into a tumor and activated by radiation.
Early clinical research has evaluated its potential in patients who may not be candidates for standard intensive chemoradiation.
Its safety and effectiveness compared with established treatments remain under investigation.
Antibody-drug conjugates and checkpoint inhibitors
Antibody-drug conjugates (ADCs) combine an antibody that recognizes a cancer-associated target with a drug designed to kill cancer cells.
Researchers are exploring ADCs alongside immunotherapy to improve treatment responses and overcome resistance.
Other experimental combinations include next-generation checkpoint inhibitors targeting LAG-3, TIM-3, TIGIT, and additional immune pathways.
These strategies are still being evaluated and are not established treatment options for most patients.
How do symptoms and causes affect head and neck cancer treatment?
Understanding the symptoms and causes of head and neck cancer can help patients recognize potential concerns and discuss their individual risk factors.
Common symptoms include persistent mouth or throat pain, difficulty swallowing, a neck lump, hoarseness, mouth sores that do not heal, or unexplained ear pain.
Important risk factors include tobacco use, heavy alcohol consumption, and certain viral infections. HPV infection is strongly associated with many oropharyngeal cancers.
Smoking cessation and limiting alcohol use may reduce the risk of head and neck cancer and support overall health during treatment.
Symptoms and risk factors alone do not determine the best therapy. Your health care provider will consider pathology, imaging, tumor location, stage, HPV status, and other clinical findings.
Managing side effects during combination cancer treatment
Combination therapies can improve cancer control, but they may also increase treatment-related side effects.
Depending on the treatments used, patients may experience fatigue, skin reactions, nausea, dry mouth, taste changes, difficulty swallowing, neuropathy, or immune-related inflammation.
Some side effects can persist after treatment ends. Nutrition support, speech and swallowing therapy, dental care, and rehabilitation may be important components of recovery.
Palliative care can also help manage pain, symptoms, emotional distress, and treatment-related complications at any stage of cancer care. It can be provided alongside treatment intended to cure or control cancer.
Tell your oncology team about new or worsening symptoms rather than waiting for your next appointment.
How do doctors choose the best neck cancer treatment?
There is no single combination therapy that is best for every patient.
A medical oncologist, surgeon, radiation oncologist, and other specialists may work together to recommend treatment based on:
Cancer type, location, and stage
Whether the cancer is newly diagnosed, recurrent, or metastatic
HPV status and other relevant biomarkers
Previous treatments
Overall health and organ function
Potential side effects
Treatment goals and patient preferences
Clinical trial availability
For some patients, the priority is eliminating the cancer while preserving swallowing or speech function. For others with advanced disease, treatment may focus on extending survival, controlling symptoms, and maintaining quality of life.
Questions to ask about combination therapies
If you are considering combination treatment, ask your healthcare team:
Which combination therapy do you recommend for my cancer?
Why is this approach better suited to my diagnosis than other options?
Is the treatment FDA-approved for my cancer type?
What benefits have clinical trials demonstrated?
What side effects should I expect?
How will treatment affect swallowing, speech, or daily activities?
Are there clinical trials I should consider?
How will we know whether treatment is working?
What happens if my cancer does not respond?
The future of head and neck cancer treatment
Combination therapies continue to expand the available treatment options for head and neck cancer. Established approaches involving chemotherapy, radiation, targeted therapy, and immunotherapy have improved outcomes for selected patient populations.
New combinations involving cancer vaccines, bispecific antibodies, radioenhancers, and other experimental treatments may offer additional options as research progresses.
Patients should discuss both established treatments and appropriate clinical trials with their healthcare team to understand which approaches are supported by evidence for their specific diagnosis.
